Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor.

Abstract

Human Gene TherapyVol. 6, No. 6 News and CommentsGene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and Soluble Interleukin 6 Receptor. University School of Medical Sciences at GreatPoland Cancer Center, Poznań, PolandPRINCIPAL INVESTIGATOR A. Mackiewicz, CO-INVESTIGATORS A. Górny, M. Laciak, J. Malicki, P. Murawa, J. Nowak, M. Wiznerowicz, COLLABORATING INVESTIGATORS R. G. Hawley, P. C. Heinrich, and S. Rose-JohnPRINCIPAL INVESTIGATOR A. MackiewiczSearch for more papers by this author, CO-INVESTIGATORS A. GórnySearch for more papers by this author, M. LaciakSearch for more papers by this author, J. MalickiSearch for more papers by this author, P. MurawaSearch for more papers by this author, J. NowakSearch for more papers by this author, M. WiznerowiczSearch for more papers by this author, COLLABORATING INVESTIGATORS R. G. HawleySearch for more papers by this author, P. C. HeinrichSearch for more papers by this author, and S. Rose-JohnSearch for more papers by this authorPublished Online:19 Mar 2008https://doi.org/10.1089/hum.1995.6.6-805AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byInsights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications28 June 2021 | Frontiers in Cell and Developmental Biology, Vol. 9Therapeutic gene modified cell based cancer vaccinesGene, Vol. 525, No. 2Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection11 May 2012 | Expert Opinion on Investigational Drugs, Vol. 21, No. 6Design of clinical trials for therapeutic cancer vaccines developmentEuropean Journal of Pharmacology, Vol. 625, No. 1-3Clinical trials of active cancer immunotherapy9 August 2007 | Expert Opinion on Investigational Drugs, Vol. 16, No. 8Whole Cell VaccinesInterleukin-6 Gene Ablation in a Transgenic Mouse Model of Malignant Skin MelanomaThe American Journal of Pathology, Vol. 166, No. 3Human cancer gene therapy with cytokine gene-modified cells23 February 2005 | Expert Opinion on Biological Therapy, Vol. 4, No. 10Immunization by Particle-Mediated Transfer of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Autologous Tumor Cells in Melanoma or Sarcoma Patients: Report of a Phase I/IB Study D.M. Mahvi, F.-S. Shi, N.-S. Yang, S. Weber, J. Hank, M. Albertini, J. Schiller, H. Schalch, M. Larson, L. Pharo, J. Gan, D. Heisey, T. Warner, and P.M. Sondel6 July 2004 | Human Gene Therapy, Vol. 13, No. 14The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells9 April 2001 | Oncogene, Vol. 20, No. 8Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptorExpert Opinion on Biological Therapy, Vol. 1, No. 2Cancer Vaccines 2000Immunology Letters, Vol. 74, No. 1Genetically modified tumour vaccines (GMTV) in melanoma clinical trialsImmunology Letters, Vol. 74, No. 1Cancer VaccinesJournal of Clinical Oncology, Vol. 17, No. 3Cytokine Gene Therapy for Human TumorsSurgical Oncology Clinics of North America, Vol. 7, No. 3GENE THERAPY FOR MELANOMA IN HUMANSHematology/Oncology Clinics of North America, Vol. 12, No. 3Immunogene Therapy of Human MelanomaGene therapy of cancerPhase I/IB Study of Immunization with Autologous Tumor Cells Transfected with the GM-CSF Gene by Particle-Mediated Transfer in Patients with Melanoma or Sarcoma University of Wisconsin, Madison, Wisconsin David M. Mahvi, P. M. Sondel, N-S Yang, M. R. Albertini, J. H. Schiller, J. Hank, J. Heiner, J. Gan, W. Swain, and R. Logrono20 March 2008 | Human Gene Therapy, Vol. 8, No. 7The therapeutic potential of interleukin-6 hyperagonists and antagonists23 February 2005 | Expert Opinion on Investigational Drugs, Vol. 6, No. 3Gene Therapy of Human Melanoma — from Animal Experiments to the Clinical TrialGene therapy of cancerReports of Practical Oncology, Vol. 1, No. 1Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccineReports of Practical Oncology, Vol. 1, No. 2 Volume 6Issue 6Jun 1995 InformationCopyright 1995, Mary Ann Liebert, Inc.To cite this article:PRINCIPAL INVESTIGATOR A. Mackiewicz, CO-INVESTIGATORS A. Górny, M. Laciak, J. Malicki, P. Murawa, J. Nowak, M. Wiznerowicz, COLLABORATING INVESTIGATORS R. G. Hawley, P. C. Heinrich, and S. Rose-John.Gene Therapy of Human Melanoma. Immunization of Patients with Autologous Tumor Cells Admixed with Allogeneic Melanoma Cells Secreting Interleukin 6 and Soluble Interleukin 6 Receptor. University School of Medical Sciences at GreatPoland Cancer Center, Poznań, Poland.Human Gene Therapy.Jun 1995.805-811.http://doi.org/10.1089/hum.1995.6.6-805Published in Volume: 6 Issue 6: March 19, 2008PDF download